- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04404595
Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers
Open-label, Multicenter, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous Anti-claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Subjects With Advanced Gastric, Pancreatic, or Other Specified Digestive System Cancers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open label, multi-center, Phase 1b/2 clinical trial to evaluate the safety and efficacy of autologous claudin18.2 chimeric antigen receptor T-cell therapy in patients with advanced gastric, pancreatic or other specified digestive system cancers.
Following consent, patients must have tumor tissue evaluated by CLDN18.2 IHC assay. Patients meeting all eligibility criteria will undergo a leukapheresis procedure to collect autologous mononuclear cells for manufacture of investigational drug product (CT041). Following manufacture of the drug product, subjects will receive preconditioning prior to CT041 infusion. All subjects will be asked to continue to undergo long-term gene safety follow-up.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Hong Ma, MD
- Phone Number: Central Phone
- Email: clinicalUS@carsgen.com
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5GH 2C1
- Princess Margaret Hospital
-
-
-
-
California
-
Duarte, California, United States, 91010
- City of Hope
-
Los Angeles, California, United States, 90089
- University of Southern California
-
San Diego, California, United States, 92093
- UCSD
-
San Francisco, California, United States, 94143
- UCSF
-
-
Florida
-
Tampa, Florida, United States, 33612
- Moffitt Cancer Center
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas Cancer Center
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Karmanos Cancer Center
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Cancer Hospital
-
-
New York
-
New Hyde Park, New York, United States, 11042
- Northwell Cancer Institute
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, United States, 10029
- The Mount Sinai Hospital
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University
-
-
Texas
-
Dallas, Texas, United States, 75246
- TX Oncology-Baylor Charles Sammons Cancer Center
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Froedtert Hospital and the Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients are eligible for screening for potential inclusion in the study:
- Voluntarily signed the ICF;
- Age ≥ 18 and < 76 years with pathologically/histologically confirmed diagnosis of adenocarcinoma of the stomach or gastroesophageal junction, referred to collectively as STAD, or pancreatic adenocarcinoma (PAAD);
- Must have CLDN18.2-positive tumor expression as determined by the CLDN18.2 IHC assay;
- Failed or been intolerant of prior lines of systemic therapy;
- Estimated life expectancy > 4 months;
- At least 1 measurable lesion per RECIST 1.1;
- ECOG performance status of 0 or 1;
- Sufficient venous access for leukapheresis collection and no other contraindications to leukapheresis;
- Patients should have reasonable CBC counts, renal and hepatic functions;
- Women of childbearing age must undergo a serum pregnancy test with negative results before screening and infusion and be willing to use effective and reliable method of contraception;
- Men must be willing to use effective and reliable method of contraception for at least 12-months after T-cell infusion;
- Sufficient nutritional status.
Exclusion Criteria:
- Pregnant or lactating women;
- HIV, active hepatitis C virus (HCV), or active hepatitis B virus (HBV) infusion;
- Any uncontrolled active infection;
- AEs from previous treatment that have not recovered;
- Patients who have clinically significant thyroid dysfunction;
- Patients allergic to any drugs of the preconditioning regimen, tocilizumab, dimethyl sulfoxide (DMSO), or CT041 CAR-CLDN18.2 T-cell;
- Patients who have received prior cellular therapy such as (CAR T, TCR, tumor-infiltrating lymphocytes) or organ transplantation; Untreated central nervous system (CNS) metastatic disease, leptomeningeal disease, or cord compression;
- Untreated CNS, leptomeningeal disease or cord compression
- Patients with heavy tumor burden such as significant lung disease
- Unstable/active ulcer or digestive tract bleeding or recent digestive surgery that may have increased risk of bleeding;
- Patients who have a history of esophageal or gastric resection with increased risk of bleeding or perforation;
- Patients requiring anticoagulant therapy such as warfarin or heparin;
- Patients requiring long-term antiplatelet therapy;
- Use of prednisone or other equivalent within 14 days before leukapheresis or preconditioning;
- Anticancer treatment within approximately 2 weeks prior to leukapheresis or approximately preconditioning;
- Major surgery less than 1 week prior to leukapheresis or 3 weeks prior to preconditioning;
- Patients have clinical significant cardiac conditions that researchers believe that participating in this clinical trial may endanger the health of the patients;
- Patients have clinical significant pulmonary conditions;
- Patients known to have active autoimmune diseases;
- Patients with second malignancies in addition to STAD or PAAD;
- Patients have significant neurologic disorders;
- Patients are unable or unwilling to comply with the requirements of clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: anti-claudin18.2 chimeric antigen receptor T-cell therapy
Phase 1b will include two parts, dose escalation phase (Cohort A) followed by a dose expansion phase (Cohort B).
Phase 2 (Cohort C) will evaluate the chosen dose in patients with advanced gastric cancer.
|
treatment with anti-claudin18.2
chimeric antigen receptor T-cell infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1b: Incidence of Treatment Related adverse events (AEs)
Time Frame: up to 18 mos
|
Incidence of Treatment Related AEs, AEs of special interest and serious adverse events (SAEs)
|
up to 18 mos
|
Phase 1b: Identification of Maximum Tolerated Dose (MTD) & incidence of Dose-limiting Toxicities (DLTs)
Time Frame: day 1 - day 28
|
Incidence of dose-limiting toxicities (DLTs)
|
day 1 - day 28
|
Phase 2: Objective Response Rate (ORR) per independent central read
Time Frame: up to 18 mos
|
Rate of subjects experiencing >/= to PR per RECIST 1.1 as determined by IRC assessment
|
up to 18 mos
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1b: Objective Response Rate (ORR) per local assessment
Time Frame: up to 18 mos
|
Rate of subjects experiencing >/= to PR per RECIST 1.1 as determined by investigator
|
up to 18 mos
|
Phase 1b/2: Duration of Response
Time Frame: up to 18 mos
|
Duration of time from first response to progression of disease as determined by investigator
|
up to 18 mos
|
Phase 1b/2: Disease Control Rate
Time Frame: up to 18 mos
|
Percentage of patients response at least 90 days as determined by investigator
|
up to 18 mos
|
Phase 1b/2: Progression free survival
Time Frame: up to 18 mos
|
duration time after CT041 treatment that patient lives without worsening of disease as determined by investigator
|
up to 18 mos
|
Phase 1b/2: Overall survival
Time Frame: up to 18 mos
|
duration time after CT041 treatment that patient lives as determined by investigator
|
up to 18 mos
|
Phase 1b/2: Utilization of Hospital Resources
Time Frame: up to 18 mos
|
Days of hospitalization during & after CT041 infusion; days of hospitalization in ICU
|
up to 18 mos
|
Phase 1b/2: Health-related Quality of Life (HRQoL)
Time Frame: Baseline - month 18
|
Change from baseline in how subjects report the satisfaction with their health as reported on the EORTC QLQ-C30; scoring uses a linear transformation to standardize the raw score such that scores range from 0-100 with a higher score requesting a higher level or function or a higher level of symptoms.
|
Baseline - month 18
|
Phase 2: Incidence of Treatment Related adverse events (AEs)
Time Frame: up to 18 mos
|
Rate of subjects experiencing >/= to PR per RECIST 1.1 as determined by investigator
|
up to 18 mos
|
Phase 1b/2: PK and bio-distribution of CT041
Time Frame: Baseline - month 18
|
Persistence of CAR transgene copy number
|
Baseline - month 18
|
Phase 1b/2: CLDN18.2 ICH Assay Performance
Time Frame: Baseline - month 18
|
Correlation of CLDN18.2 expression level with tumor response
|
Baseline - month 18
|
Phase 1b/2: Anti-CT041 drug antibodies
Time Frame: day 0 - month 18
|
Number of subjects with anit-CT041 drug antibodies
|
day 0 - month 18
|
Phase 1b/2: Cytokine expression level in blood after CT041 infusion
Time Frame: day 0 - month 6
|
evaluate cytokine (IL-6 et al) expression levels in patients treated with CT041
|
day 0 - month 6
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Harry H Yoon, MD, MAYO
- Principal Investigator: Dae Won Kim, MD, Moffitt
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CT041-ST-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Cancer
-
City of Hope Medical CenterRecruitingGastric Cancer | Gastric Adenocarcinoma | Gastric Cancer Stage IV | Gastric Neoplasm | Gastric Cancer Metastatic to Lung | Gastric Cancer Stage | Gastric Cancer Metastatic to Liver | Gastric Cancer Stage III | Gastric Cancer Stage II | Gastric Lesion | Gastric Cancer in Situ | Gastric Cancer Stage IIIB | Gastric... and other conditionsUnited States, Japan
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Pathologic Stage... and other conditionsUnited States
-
City of Hope Medical CenterActive, not recruitingAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage IB Gastric Cancer AJCC v8 | Pathologic Stage II Gastric Cancer AJCC v8 | Pathologic... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedGastric Adenocarcinoma | Stage IV Gastric Cancer | Stage II Gastric Cancer | Stage III Gastric CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedGastroesophageal Junction Adenocarcinoma | Gastric Cardia Adenocarcinoma | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage IIIB Gastric Cancer AJCC v7United States
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric CancerUnited States
-
National Cancer Institute (NCI)CompletedGastric Cancer | Gastric NeoplasmsUnited States
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedGastric Cancer | Esophageal Cancer | Adenocarcinoma Gastric | Metastatic Gastric Cancer | GastroEsophageal Cancer | HER2 Positive Gastric CancerGermany
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RecruitingGastric Adenocarcinoma | Epstein-Barr Virus Positive | Mismatch Repair Protein Deficiency | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage III Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage... and other conditionsUnited States
Clinical Trials on CT041
-
CARsgen Therapeutics Co., Ltd.Fudan UniversityRecruiting
-
CARsgen Therapeutics Co., Ltd.Fudan University; Peking University Cancer Hospital & InstituteRecruitingStudy to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell InjectionPancreatic Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction AdenocarcinomaChina